Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by University of Arkansas
Sponsor:
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT01622582
First received: June 15, 2012
Last updated: August 19, 2014
Last verified: August 2014
  Purpose

Engraftment Syndrome after Autologous Stem Cell Transplant: Retrospective Review in Patients with Multiple Myeloma


Condition
Multiple Myeloma

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma

Resource links provided by NLM:


Further study details as provided by University of Arkansas:

Primary Outcome Measures:
  • number of patients developing Engraftment syndrome following stem cell transplant [ Time Frame: 6 months post-transplant ] [ Designated as safety issue: Yes ]
    A retrospective review where subjects medical records are studied for development of engraftment syndrome 6 months after stem cell transplant


Estimated Enrollment: 1200
Study Start Date: January 2006
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Detailed Description:

A retrospective chart review series will be performed fpr subjects enrolled from 1/1/2006.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with Multiple Myeloma, developing engraftment syndrome

Criteria

Inclusion Criteria:

  • Patients with Multiple Myeloma, developing engraftment syndrome

Exclusion Criteria:

  • Patients with Multiple Myeloma, with no features of engraftment syndrome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01622582

Locations
United States, Arkansas
University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Naveen sanath kumar, MD, MHSA    501-681-1972    nsanathkumar@uams.edu   
Principal Investigator: Senu Apewokin, MD         
Sub-Investigator: Naveen Sanath Kumar, MD, MHSA         
Sponsors and Collaborators
University of Arkansas
Investigators
Principal Investigator: Senu Apewokin, MD UAMS
  More Information

No publications provided

Responsible Party: University of Arkansas
ClinicalTrials.gov Identifier: NCT01622582     History of Changes
Other Study ID Numbers: UARK 2008-30
Study First Received: June 15, 2012
Last Updated: August 19, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Arkansas:
Multiple Myeloma, Engraftment syndrome

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Syndrome
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Disease
Pathologic Processes

ClinicalTrials.gov processed this record on September 18, 2014